Hereditary Spherocytosis and Anemia Classification
Hereditary spherocytosis typically presents as a normocytic anemia, though it can occasionally appear microcytic depending on disease severity and the specific membrane protein defect involved.
Understanding the Anemia Pattern in Hereditary Spherocytosis
Hereditary spherocytosis (HS) is characterized by chronic hemolysis with anemia, jaundice, and splenomegaly 1, 2. The anemia classification in HS is more nuanced than a simple categorical assignment:
Mean Corpuscular Volume (MCV) Characteristics
- The anemia in HS is generally normochromic and normocytic 3
- However, MCV can vary based on the underlying membrane protein defect 4, 5
- Spectrin-deficient patients tend to have slightly lower MCV values compared to band 3-deficient patients 5
- Variants in the ANK1 death domain are associated with lower MCV and MCH levels compared to other ANK1 domains 4
Key Hematologic Features
The blood picture in HS shows several characteristic findings beyond just MCV:
- Mean corpuscular hemoglobin concentration (MCHC) is typically elevated, reflecting the hyperchromic nature of spherocytes 1
- Reticulocytosis is usually present (though not proportional to hemolysis severity in non-splenectomized patients) 6
- Anisocytosis and poikilocytosis are common, with variable proportions of echinocytes particularly after splenectomy 6
- Hemoglobin levels are generally reduced (23 of 26 patients in one series had anemia) 2
Clinical Context Matters
The classification as normocytic can be misleading in isolation because:
- Red cell morphology in HS is usually unremarkable on routine examination, displaying only some degree of anisocytosis and poikilocytosis 6
- The anemia is indistinguishable from anemia associated with other chronic conditions when relying solely on MCV 3
- Spherocytes themselves may not be prominent on blood smear, making diagnosis challenging without specialized testing 1, 7
Diagnostic Pitfalls to Avoid
Do not rely on MCV alone to exclude or diagnose HS. The key diagnostic approach includes:
- Elevated MCHC and specialized parameters like hyper-dense cell percentage (% Hyper), % Hyper-He, or HPR are more specific indicators 1
- Eosin-5-maleimide (EMA) binding test provides high sensitivity and specificity for screening 1, 7, 8
- Osmotic fragility testing (acidified glycerol lysis test combined with NaCl test on incubated blood) reaches 99% sensitivity 5
- Genetic testing via next-generation sequencing confirms diagnosis by identifying mutations in ANK1, SPTB, SPTA1, SLC4A1, or EPB42 genes 1, 2, 4
Bottom Line for Clinical Practice
While HS is classically taught as a normocytic anemia, the MCV can range from microcytic to normocytic depending on the specific genetic defect and disease severity. The most reliable approach is to:
- Suspect HS in any patient with chronic hemolysis (elevated reticulocytes, LDH, reduced haptoglobin, elevated bilirubin) where immune-mediated processes, unstable hemoglobins, and paroxysmal nocturnal hemoglobinuria have been excluded 6
- Use specialized erythrocyte parameters and EMA binding test for screening rather than relying on MCV classification 1, 7
- Confirm with genetic testing when clinical suspicion is high, as this provides definitive diagnosis and has important implications for family counseling 2, 4